Reduction of late-onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus.

Arnaud Devresse,Marianne Leruez-Ville,Anne Scemla,Véronique Avettand-Fenoel,Lise Morin,Xavier Lebreton,Claire Tinel,Lucile Amrouche,Lionel Lamhaut,Marc Olivier Timsit,Julien Zuber,Christophe Legendre,Dany Anglicheau

TRANSPLANT INTERNATIONAL（2018）

引用 7|浏览47

暂无评分

摘要

our data suggest that de novo use of EVL may reduce late-onset CMV primary disease after the withdrawal of antiviral prophylaxis in kidney transplantation patients. This article is protected by copyright. All rights reserved.

查看译文

关键词

Cytomegalovirus,everolimus,kidney transplantation,primary disease

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要